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Regulatory T cells (Tregs) play an indispensable role in the prevention of autoimmune dis-
ease, as interferon gamma (IFNγ) mediated, lethal auto-immunity occurs (in both mice and
humans) in their absence. In addition, Tregs have been implicated in preventing the onset
of autoimmune and auto-inflammatory conditions associated with aberrant IFNγ signal-
ing such as type 1 diabetes, lupus, and lipopolysaccharide (LPS) mediated endotoxemia.
Notably, suppressor of cytokine signaling-1 deficient (SOCS1−/−) mice also succumb to
a lethal auto-inflammatory disease, dominated by excessive IFNγ signaling and bearing
similar disease course kinetics to Treg deficient mice. Moreover SOCS1 deficiency has
been implicated in lupus progression, and increased susceptibility to LPS mediated endo-
toxemia. Although it has been established that Tregs and SOCS1 play a critical role in the
regulation of IFNγ signaling, and the prevention of lethal auto-inflammatory disease, the
role ofTreg/SOCS1 cross-talk in the regulation of IFNγ signaling has been essentially unex-
plored. This is especially pertinent as recent publications have implicated a role of SOCS1
in the stability of peripheralTregs.This review will examine the emerging research findings
implicating a critical role of the intersection of the SOCS1 and Treg regulatory pathways in
the control of IFN gamma signaling and immune system function.
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INTRODUCTION
The primary role of the immune system is to eliminate patho-
genic, infectious agents and altered self (cancers) (1–3). Inter-
feron gamma (IFNγ) plays a critical role in the capacity of the
immune system to recognize and eliminate pathogenic agents
through increased presentation of antigens by antigen presenting
cells, induction of an anti-viral state in infected cells, and medi-
ation of anti-microbial effector functions (4). In addition, IFNγ
serves to mediate the destruction of cancerous cells by inducing
an anti-proliferative state, enhancing NK cell activity, and medi-
ating antibody production (4–6). Conversely, aberrant immune
system functions can result in the destruction of self-tissues (auto-
immunity) and dysbiosis of natural gut flora communities (1, 7).
It is therefore essential that IFNγ, a central effector of the immune
system, be carefully regulated. Foxp3+ regulatory T cells (Tregs),
and the intracellular protein suppressor of cytokine signaling-1
(SOCS1), are two critical regulators of IFNγ signaling. In this
review we will: (1) define the role of these two mechanisms in
the regulation of IFNγ signaling, (2) examine evidence suggesting
cross-talk between these two pathways, and (3) explore emerging
research whereby IFNγ signaling is regulated through the use of
SOCS1 mimetic peptides.
IFN GAMMA SIGNALING
The sole type II interferon, IFNγ is a multipotent cytokine secreted
by activated T cells and natural killer cells and is responsible
for the modulation of many facets of immune response. IFNγ
exerts its effects through interactions with the IFNγ receptor com-
plex (IFNGR) on the surface of target cells. The IFNGR is a
heterodimeric complex that consists of an alpha subunit IFNGR1
(90 kDa) and a beta subunit IFNGR2 (60 kDa) (8, 9). IFNGR1
binds to IFNγ with high affinity whereas IFNGR2, although con-
tributing to ligand binding and required for signaling, binds to
IFNγ with a significantly lower affinity (9, 10). The binding
involves crosslinking two molecules each of IFNGR1 and IFNGR2.
Subsequent to ligand binding, tyrosine kinases JAK1 (constitu-
tively associated with IFNGR1) and JAK2 (constitutively asso-
ciated with IFNGR2) become phosphorylated and subsequently
activate STAT1 through phosphorylation (9, 11, 12). It is then
thought that phosphorylated, activated STAT1 translocates to the
nucleus, where it mediates the transcription of IFNγ associated
proteins. The immediate effects of IFNγ signaling occur rapidly as
JAK1, JAK2, IFNGR1, and Stat1 are phosphorylated within 1 min
of IFNγ treatment (4).
IFNγ AND DISEASE
Although IFNγ signaling is critical for the generation of effector
functions involved in the elimination of cancers and pathogenic
microorganisms, the signaling must be carefully regulated to pre-
vent excessive inflammation. The potential deleterious effects of
IFNγ signaling are also underscored by the fact that administra-
tion of IFNγ to neonatal mice results in a lethal auto-inflammatory
disease (13, 14). Significantly, excessive IFNγ signaling has been
associated with several autoimmune diseases including systemic
lupus erythematosus (SLE) in both patients and rodent mod-
els of disease (15–18). SLE is a debilitating autoimmune disease
with numerous medical manifestations including leucopenia, skin
rashes, and damage to heart and kidneys. Moreover, ongoing
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research strategies for treatment of autoimmune diseases such a
lupus include the use of antibodies targeting cytokines involved in
disease progression, such as IFNγ (15).
In addition to tolerance to self-tissues, the immune system
must also maintain a balance between the elimination of infectious
microorganisms and the tolerance of mutualistic microorganisms,
which both regulate mammalian metabolic events and immune
system development (19). Lipopolysaccharide (LPS) endotoxin,
by Gram negative bacteria, and Staphylococcal enterotoxins (SE),
by Gram positive bacteria, pose significant risks to human health
by their capacity to dysregulate immune tolerance mechanisms
and generate a lethal inflammatory environment, with excess
production of IFNγ (20). This is especially true in the case of
combination challenges (infections are commonly polymicrobial),
as it has been established that the combination challenges of
Staphylococcal enterotoxin A (SEA) and LPS mediate more severe
inflammatory environments in intact mice (20). SEA, which is a
member of the superantigen toxins produced by Staphylococcus
aureus, activates T lymphocytes possessing T cell receptors (TCR)
of varying V-beta specificities, and is capable of mediating toxic
shock syndrome. SEA crosslinks the antigen presenting cell MHC
molecule, with the TCR V-beta chain, resulting in the production
of abundant pro-inflammatory cytokines such as tumor necrosis
factor alpha (TNFα), IFNγ, interleukin 1 (IL1), and IL6 (20). A
hallmark of the adaptive immune system is antigenic specificity
(21). Whereas a conventional T cell antigen mediates the activa-
tion of T lymphocytes on the order of one T cell clone/10,000
lymphocytes, as many as one in five T lymphocytes can be acti-
vated by the superantigen (22). Moreover the excessive activation
of T lymphocyte clones occurs at a fraction of the concentra-
tion required to mediate conventional T lymphocyte activation.
Notably, staphylococcal superantigens account for nearly 45%
of all cases of food poisoning (23). IFNγ and IL6 produced in
response to microbial insult contribute to fever, nausea, vom-
iting, and diarrhea associated with the food poisoning. Given
the potential for IFNγ signaling to result in auto-immunity or
excessive responses directed toward microorganisms, the immune
system has developed regulatory mechanisms to limit IFNγ sig-
naling, which are potential targets of modulation in excessive
inflammatory environments.
REGULATORY T CELLS AND AUTO-IMMUNITY
Despite the fact that T cells bearing specificity to self-peptides exist
in nearly all individuals, autoimmune diseases are in limited num-
bers when compared to other sources of human disease (24, 25),
thus underscoring the presence of tolerance mechanisms. Beyond
central tolerance, one mechanism of active immune tolerance is
Tregs. Although several distinct T cell populations possessing reg-
ulatory function have been described, CD4+ Tregs bearing the
Foxp3+ transcription factor and constitutive expression of CD25
represent one of the lineages most characterized to date (26–28).
However, it is important to note that Foxp3 alone is not sufficient
to recapitulate the entire Treg signature (29), suggesting that addi-
tional Treg modulating genes likely remain to be characterized.
Tregs have the capacity to suppress immune responses mediated
by numerous cell types including macrophages, CD4+ T cells, and
CD8+ T cells (30–34). The importance of functional Tregs in the
prevention of auto-immunity is underscored by the fact that the
adoptive transfer of Tregs into type 1 diabetes (35), experimental
allergic encephalomyelitis (36), inflammatory bowel disease (37),
and arthritis (38) rodent models resulted in the prevention/cure
of disease.
Regulatory T cells, under the pseudonym suppressor T cells,
have origins within the pioneering studies of Gershon followed
by a rebirth powered largely by the Shevach and Sakaguchi lab-
oratories (39). Tregs, along with other T lymphocytes, originate
from the thymus as illustrated in seminal studies showing that day
3 thymectomy of neonatal mice resulted in the development of
organ specific autoimmune diseases, which could be prevented by
the administration of CD4+CD25+ T lymphocytes from healthy
mice. Naturally occurring, thymic derived Foxp3+ Tregs constitute
approximately 3–5% of the CD4+ CD8− thymocyte population
(40) and are generally present within the medullary region of the
thymus, the location of the most mature thymocytes (41). Further
advances in the characterization of Tregs were made after the dis-
covery that the lethal pathology observed in Scurfy mice was due
to defective Foxp3. Scurfy mice, which lack CD4+ CD25+ Foxp3+
Treg, die of a perinatal auto-inflammatory disease within 21 days
after birth (39). Moreover, Scurfy mice die of massive infiltra-
tions of activated leukocytes in multiple organs with autoimmune
disease manifestations including lymphadenopathy, splenomegaly,
anemia, and wasting (39). Notably, depletion of Th1 responses
through the breeding of Scurfy mice to IFNGR1 or Tbet defi-
cient backgrounds, results in prolonged survival of Scurfy mice
(42). These results underscore the role that Tregs serve in critically
regulating Th1 responses.
To date, there are two characterized populations of Foxp3+
Tregs: naturally occurring Tregs that develop in the thymus
(nTregs); and induced Tregs (iTregs) which are generated within
peripheral organs from naïve CD4+ CD25−Foxp3− T lympho-
cytes (39, 43–45). Both nTregs and iTregs are thought to play a
significant role in the regulation of immune responses, with nTregs
focused on immunity directed against self-peptides and iTregs
limiting immune pathology in response to commensal bacteria.
Markers used to distinguish iTregs from nTregs include neuropilin-
1 (46) and the transcription factor Helios (47). Generation of
peripheral Tregs can be mediated through the expansion of nTregs
in the presence of endogenous peptides specific to Treg TCR,
administration of low levels of cognate antigen, or transforming
growth factor β (TGFβ) administration (48–51).
The survival and function of Tregs is critically dependent upon
cytokines, such as Interleukin 2 (IL2) which is required for the sur-
vival of nTregs (52), and enhanced peripheral generation of iTregs
(53, 54). In contrast, IL6 inhibits the generation of iTregs while
favoring the generation of IL-17 secreting cells (55). Although
Tregs can inhibit the production of IFNγ, Th1 associated cytokines
IL27 and IFNγ have been shown to increase TGF-β induced Foxp3
expression (56, 57). However, other studies have shown that a
Th1 response inhibits the generation of peripheral Tregs (58). It
is possible that the ability of IFNγ to up-regulate the IL2 recep-
tor (CD25) (59) on lymphocytes may contribute to the increased
FoxP3 expression observed, although further studies are necessary.
It is thus clear that the differentiation, survival, and regulation
of Tregs is dependent upon complex interactions with cytokines.
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Conversely, it is also clear that the regulation of inflammatory
cytokines, such as IFNγ, is also critically dependent on Tregs.
REGULATION OF IFNγ SIGNALING THROUGH SOCS
PROTEINS
In addition to regulation of IFNγ signaling by Tregs, it has become
evident that the SOCS family of intracellular proteins also plays
a pivotal role in such signaling (60). The SOCS protein fam-
ily, identified in 1998, currently possesses eight family [SOCS1
to SOCS7 and cytokine-inducible SH2 protein (CIS)] members,
which negatively regulate cellular responses to cytokines in a feed-
back inhibition fashion (61). SOCS proteins are induced by several
cytokines and act to inhibit the signaling of the cytokine that medi-
ated their generation (62). SOCS proteins act through at least
two mechanisms: (1) SOCS1 possesses a kinase inhibitory region
(KIR) that binds to JAKs, thus inhibiting further cytokine signal-
ing and (2) SOCS1 contains a region known as the SOCS box,
which targets bound proteins to the proteasome for degradation
(60). Whereas all of the SOCS proteins possess a large central
SH2 domain and a C-terminal SOCS box, the N-terminal (12-
amino acid long, adjacent to the SH2 domain) KIR region has
only been identified in SOCS1 and SOCS3. While SOCS1 was
initially identified as a regulator of IL6 signaling (63), it later
became identified as a regulator of IFNγ. Mice lacking SOCS1
(SOCS1−/−) die within 21 days after birth, and are characterized
by excessive IFNγ signaling and massive inflammatory infiltration
of auto-immune leukocytes into several organs including lungs,
pancreas, liver, and heart (63). Neonatal lethality in SOCS1−/−
mice is believed to be due to excessive IFNγ signaling, as the treat-
ment of SOCS1−/− mice with IFNγ neutralizing antibodies or
breeding to an IFN gamma deficient background rescues mice
from neonatal lethality (64). SOCS1 deficient mice, made trans-
genic to express SOCS1 protein possessing the KIR region, but
lacking the SOCS box, could survive peri-lethality with approxi-
mately 20% surviving long-term (65). Functionally, the regulation
of IFNγ signaling by SOCS1 is mediated by inhibition of JAK2
activity, but potentially also through the regulation of tyrosine
kinases TYK2 and JAK1.
SOCS1 AND AUTO-IMMUNITY
In addition to the lethal, auto-inflammatory disease that occurs
within SOCS1-KO mice, deficiencies in SOCS1 are also specifi-
cally linked to the onset and progression of SLE. SOCS1−/− mice,
with forced expression of SOCS1 in B and T lymphocytes, and
SOCS1+/− mice survive perinatal lethality but develop a lupus-
like disease (66, 67). The F1 progeny of New Zealand Black and
New Zealand White (NZB/W) mice are a well-established model
for spontaneous SLE (68). Notably, splenocytes present in diseased
NZB/W mice have a reduced capacity to up-regulate SOCS1 in
response to IFNγ (16). Moreover, the administration of a tolero-
genic peptide, hCDR1, prevented lupus onset in NZB/W mice and
enhanced production of SOCS1. In addition, the enhanced SOCS1
expression was correlated to reductions in IFNγ production and
STAT 1 activation in NZB/W mice (16). Although there is good
evidence in rodent studies denoting a role for SOCS1 expression
in the prevention of murine lupus, more studies are necessary to
establish the translational value of this finding.
Moreover it has been shown that SOCS1 signaling plays an
important role in moderating signaling directed toward micro-
bial antigens, or microbial lymphocyte mitogens, as deficiencies in
SOCS1 result in hyper-responsiveness to LPS (69). Although mice
are more resistant to the individual effects of SEA or LPS than
humans, immunological tolerance mechanisms regulating lethal
inflammation in mice are overcome when co-challenged with SEA
and LPS (20). Significantly, single administration of LPS to SOCS1
deficient mice resulted in lethal inflammation (69, 70), underscor-
ing the critical role of SOCS1 in the maintenance of tolerance and
prevention of lethal inflammation.
Treg/SOCS1 CROSS-TALK REGULATION OF IFNγ SIGNALING
Auto-immunity is due largely to the cumulative effects of
auto-antibody production (71), dysregulated pro-inflammatory
cytokine signaling (72), and decreased regulatory T cell func-
tion (Tregs) (73, 74). It is likely, however, that the cumulative
effects promoting auto-immunity are somewhat interdependent
as we have previously shown that Tregs can inhibit auto-reactive
T cell proliferation (75), auto-antibody production (34), and
pro-inflammatory cytokine production (76). In similar fashion,
immune system regulatory mechanisms are also interconnected.
For example, thymic events not only mediate central tolerance,
which limits the export of self-reactive T lymphocytes into the
periphery, but also is the location o f nTreg development. Notably,
several recent studies have shown that SOCS1 and Foxp3+ Treg
regulation of inflammation are also interconnected. Similar to
Scurfy mice, survival of SOCS1−/−mice was greater with the adop-
tive transfer of wild-type conventional cells combined with Tregs
compared to transfers of Tregs alone (77, 78). In addition, Scurfy
and SOCS1 deficient mice both have significantly expanded pop-
ulations of peripheral CD44hiCD4+ T lymphocytes (42, 64). The
presence of CD44hi cells is indicative of homeostatic prolifera-
tion. Moreover, recent microRNA (miR) studies link Tregs and
SOCS1. MicroRNA 155 (miR-155) is highly expressed in Tregs,
and is regulated by the transcription factor Foxp3 (79). Foxp3
binds to the promoter region of miR-155 host gene bic, mediating
miR-155 up-regulation, which is then thought to down-regulate
SOCS1 expression (80, 81). High levels of Foxp3 therefore drive
up miR-155 expression, down-modulate SOCS1, and enhance the
thymic development of Tregs (78, 81, 82). Notably, however, miR-
155 is not required for peripheral survival of Tregs or suppressor
function (83). Although Rag gene deficient mice are free of sponta-
neous colitis, SOCS1−/−Rag2−/− mice develop severe colitis (84).
However, the adoptive transfer of IL10-producing-Tregs is suf-
ficient to prevent colitis in SOCS1−/−Rag2−/− mice (84), again
underscoring the interconnected nature of SOCS1 signaling and
regulatory Tregs in the regulation of immune responses. Signif-
icantly, onset of lethal auto-inflammatory disease in SOCS1−/−
mice is correlated with a decrease in Foxp3+ Tregs, thereby suggest-
ing a critical role of SOCS1 in the peripheral stability of Tregs (78).
Moreover, in the absence of SOCS1, Foxp3+ T cells produce the
inflammatory cytokines IL-17 and IFNγ (85). Further, recent stud-
ies show that Ubc13, lysine specific ubiquitin-conjugating enzyme,
regulates SOCS1 expression and IL10 production in Tregs (86).
This finding is significant as Ubc13 mutation does not affect Foxp3
expression in T lymphocytes; however, Ubc13 deficient Foxp3+ T
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FIGURE 1 | From inhibitor to contributor: figure representing the
critical role of SOCS1 in the stability and function of Foxp3+ Tregs. (Top)
Tregs possessing Foxp3 and SOCS1 inhibit clonal expansion and the
production of inflammatory effector cytokines such as IFNγ (red circles) and
IL-17 (purple circles) by conventional T cells (Tconv), thus maintaining
immune homeostasis. (Bottom) T cells possessing Foxp3, but lacking
SOCS1, produce inflammatory cytokines and promote Tconv generation of
an inflammatory environment. Thus exTregs expressing Foxp3, but lacking
SOCS1, can promote auto-immunity.
lymphocytes acquire IFNγ or IL-17 producing inflammatory phe-
notypes (86). Inflammation is regulated through two important
arms of the immune system; the intracellular proteins SOCS1 (60,
63) and Foxp3+ Tregs (52). Significantly, the studies presented
herein implicate a role of SOCS1 in the stability of Tregs, sug-
gesting that loss of SOCS1 function also inhibits Treg function
(Figure 1).
SOCS MIMETICS AS THERAPEUTICS AGAINST
AUTO-IMMUNITY AND INFLAMMATION
Given the critical importance of SOCS1 in moderating IFNγ sig-
naling directly, and in stabilizing the Treg phenotype (78, 86),
methods to modulate SOCS1 function would likely have signif-
icant therapeutic potential. Two factors limit the direct use of
SOCS1 protein as a therapeutic: (1) SOCS1 is extremely difficult
to produce in pure form and (2) since it functions intracellularly,
there is also the challenge of it being internalized by cells so that
interaction with JAKs can occur.
We have addressed these problems with SOCS1 by develop-
ment of small peptide SOCS1 mimetics. The focus has been
on the 12-amino acid KIR of SOCS1 where we initially devel-
oped a 12-residue peptide based on a hydropathic complementary
algorithm (87). The resultant tyrosine kinase inhibitory peptide
(Tkip), WLVFFVIFYFFR, specifically bound to the activation loop
sequence, 1001LPQDKEYYKVKEP, of JAK2 (88). Tkip blocked
autophosphorylation of JAK2 as well as that of JAK2 phospho-
rylation of receptor subunit IFNGR1 and the corresponding tran-
scription factor STAT1α. Tkip also blocked phosphorylation of the
epidermal growth factor tyrosine kinase receptor (EGFR), whose
function is also inhibited by SOCS1 (87). Like SOCS1, however,
Tkip did not inhibit receptor tyrosine kinase VEGF kinase activity
(87). Attachment of a lipophilic palmitate residue to Tkip (lipo-
Tkip) allowed cell penetration for study of function. In this regard,
cells treated with lipo-Tkip showed inhibition of IFNγ induced
anti-viral activity against EMC virus in WEHI-3 cells and down-
regulation of IFNγ induced expression of MHC class I on WISH
cells (87).
Tkip protected mice against experimental auto-immune
encephalomyelitis (EAE), a mouse model of multiple sclerosis,
both in terms of induction of acute EAE, relapsing/remitting EAE,
and chronic EAE (89). Importantly, it also showed therapeutic
efficacy when treatment was initiated after appearance of par-
alytic symptoms and central nervous system (CNS) pathology
(89). These studies involved injection of lipo-Tkip at 63µg/dose
IP every other day and were the first to show that a SOCS1 mimetic
had therapeutic potential in treating an auto-immune disorder.
As indicated, Tkip was developed based on the hydropathic
complementary algorithm without an initial consideration of
SOCS1-KIR. However, of three sites of homology between Tkip
and KIR, residues F56 and F59 of KIR are of particular interest as
mutational analysis has shown that they are critical for KIR binding
to JAK2 (88). We thus synthesized SOCS1-KIR and determined its
binding to JAK2 activation loop, JAK2(1001–1013), with phospho-
rylated and non-phosphorylated tyrosine 1007 (88). SOCS1-KIR
bound to phosphorylated activation loop, pJAK2(1001–1013),
with higher affinity than to unphosphorylated activation loop.
Unlike Tkip, however, SOCS1-KIR did not block JAK2 autophos-
phorylation, but like Tkip it did block STAT1α phosphorylation.
Thus, Tkip and SOCS1-KIR both recognized JAK2 activation loop,
but not in the same precise manner.
We synthesized lipo-SOCS1-KIR and determined its thera-
peutic efficacy in a murine relapsing/remitting model of EAE.
Treatment of SJL/J mice with SOCS1-KIR beginning 12 days post-
immunization with myelin basic protein (MBP) resulted in mini-
mal symptoms of EAE, while most control treated mice developed
paraplegia (90). Th1 and Th17 cells via IFNγ and IL-17, respec-
tively, are thought to play critical roles in the pathogenesis of
EAE and multiple sclerosis (91). SOCS1-KIR treatment suppressed
interleukin-17A (IL-17A) production by MBP-specific lympho-
cytes, as well as MBP-induced lymphocyte proliferation. When
treated with IL-23, a key cytokine in the terminal differentiation
of IL-17-producing cells, MBP-sensitized cells produced IL-17A
and IFNγ; SOCS1-KIR was able to inhibit the production of these
cytokines (90). SOCS1-KIR also blocked IL-23 and IL-17A acti-
vation of STAT3. There is a deficiency of SOCS1 and SOCS3
expression in CD4+ T cells that infiltrate the CNS in EAE, reflect-
ing a deficiency in regulation. Consistent with therapeutic efficacy,
SOCS1-KIR reversed the cellular infiltration of the CNS that is
associated with EAE (90). These results with an auto-immune
neurological model suggest the potential of SOCS mimetics as
therapeutics for auto-immune and inflammatory disorders.
The immuno-modulatory potential of lipo-SOCS1-KIR was
also examined in SOCS1−/− mice, which die within 21 days of
birth of an IFNγ mediated, auto-inflammatory disease (78). Sig-
nificantly, lipo-SOCS1-KIR administration, in combination with
CD4 T cell adoptive transfer, was sufficient to extend the sur-
vival of SOCS1−/− mice (78). The survival of the SOCS1−/− mice
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receiving the combined treatment was similar to previous studies
utilizing mice where SOCS1 contained a KIR region, but lacked
a SOCS box (65). Moreover the SOCS1-KIR/CD4 T cell adoptive
transfer treatment, decreased leukocytic infiltrations of organs,
decreased inflammation overall, and decreased IFNγ serum levels.
In particular, the combined treatment mediated a very notice-
able increase of peripheral Foxp3+ Tregs, both number and fre-
quency, which correlated with the increased survival of SOCS1−/−
mice (78). This study suggests that administration of mimetics of
SOCS1 may potentially enhance Treg mediated regulation of the
immune response.
There is also evidence that SOCS1-KIR has therapeutic poten-
tial in auto-immune/inflammatory skin disorders such as psoriasis
(92). First, others have confirmed the mimetic activity of SOCS1-
KIR and have made modifications in residues for a SOCS1-KIR
variant that possessed specific activity similar to that of SOCS1-
KIR (93). IFNγ plays a key role in psoriasis related pathogenesis
of the skin via its activation of keratinocytes (94). Overexpression
of SOCS1 in keratinocytes has previously been shown to reduce
the inflammation and to restore homeostasis to the skin (95). The
SOCS1-KIR mimetic variant inhibited IFNγ induced inflamma-
tion in human keratinocytes, which was reflected by inhibition of
JAK2, IFNGR1, and STAT1α phosphorylation. The inhibition at
the level of JAK2 autophosphorylation suggests that the SOCS1-
KIR variant (called PS-5) functioned similarly to that of Tkip (92).
Consistent with reduced phosphorylation, PS-5 reduced ICAM-1,
HLA-DR, CXCL-10, and CCL-2 inflammatory gene expression.
These SOCS1 mimetic results suggest the potential of treatment
of psoriasis-type disorders with SOCS1 mimetics.
FROM SOCS1-KIR TO A SOCS1 ANTAGONIST
The fact that KIR of SOCS1, SOCS1-KIR, can bind to a
peptide, pJAK2(1001–1013), that corresponds to the activation
loop of phosphorylated JAK2, pJAK2, raised the possibility that
pJAK2(1001–1013) could function as an antagonist of SOCS1
(88). We have thus demonstrated under four different types of
experiments that pJAK2(1001–1013) possessed SOCS1 antago-
nist properties. First, pJAK2(1001–1013) enhanced suboptimal
IFNγ activity. Second, prostate cancer cells transfected for con-
stitutive production of SOCS1 protein had reduced activation
of STAT3 by IL6 treatment. pJAK2(1001–1013) reversed the
SOCS1 effect. Third, pJAK2(1001–1013) enhanced IFNγ activa-
tion of the luciferase reporter gene via the GAS promoter. Fourth,
pJAK2(1001–1013) enhanced antigen-specific splenocyte prolifer-
ation. Treatment of cells with IFNγ resulted in activation of the
SOCS-1 gene in approximately 90 min and it has been proposed
that this is associated with the physiological attenuation of the
IFNγ response by SOCS1 (64). Consistent with this, it has been
reported that siRNA inhibition of SOCS1 expression in bone mar-
row dendritic cells resulted in enhanced cytotoxic T lymphocyte
(CTL) activity and IFNγ production by ELISPOT, culminating in
enhancement of antitumor immunity (96).
Recently, the SOCS1 antagonist was shown to enhance antigen-
presentation and CTL activity of human dendritic cells (97).
Specifically, pJAK2(1001–1013) up-regulated the expression of the
maturation marker (CD83) and co-stimulatory molecule (CD86)
of monocyte-derived mature dendritic cells (mDCs), potentiated
FIGURE 2 | Proposed model of immune regulation by SOCS1 mimetic
peptides and antagonists. (Top) Cell penetrating SOCS1 antagonist
peptides (pink loop) are internalized by various immune cells: macrophages
(Mac), dendritic cells (DCs), regulatory T cells (Treg), and conventional T cell
(T conv) where they antagonize the immuno-suppressive effects of native
SOCS1. Inflammatory processes are enhanced, thus facilitating the
elimination of cancers and viral infections. (Bottom) Cell penetrating
SOCS1-KIR, which mimics the function of native SOCS1 (blue loop), is
internalized by various immune cells (as above) where it enhances the
immuno-suppressive effects of native SOCS1. Inflammatory processes are
inhibited by cell penetrating SOCS1-KIR, thus inhibiting diseases which
require dysregulated inflammation.
the capacity of mDCs to induce T cell proliferation, stimulated the
secretion of pro-inflammatory cytokines, and enhanced the cyto-
toxicity of tumor cell antigen-specific CTLs activated by human
gastric cancer cell total RNA-electroporated mDCs. At the level of
transcription, pJAK2(1001–1013) enhanced STAT1 activation.
Thus, just as the SOCS mimetics can inhibit inflammatory
cytokine activity in auto-immunity, the SOCS1 antagonist can
enhance immune activity for treatment of infections and cancers
(Figure 2).
CONCLUSION
The immune regulatory mechanisms of Tregs and SOCS1 play a
critical role in maintaining the balance between the effective clear-
ances of pathogens and maintaining tolerance to self-tissues and
mutualistic microorganisms. Notably, recent studies implicate a
significant role of SOCS1 in the peripheral survival and pheno-
typic stability of Tregs, suggesting that defects in the SOCS1 arm
of immune homeostasis will also cause defects in the Treg arm of
homeostasis. Moreover, the use of peptides which mimic SOCS1
signaling may have therapeutic efficacy in the treatment of auto-
immunity by restoring the SOCS1 and Treg immuno-modulatory
pathways.
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